Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer.
Liu J, Duan Z, Guo W, Zeng L, Wu Y, Chen Y, Tai F, Wang Y, Lin Y, Zhang Q, He Y, Deng J, Stewart RL, Wang C, Lin PC, Ghaffari S, Evers BM, Liu S, Zhou MM, Zhou BP, Shi J.
Liu J, et al. Among authors: zhou bp, zhou mm.
Nat Commun. 2018 Dec 5;9(1):5200. doi: 10.1038/s41467-018-07258-y.
Nat Commun. 2018.
PMID: 30518851
Free PMC article.